Ipca Takes Full Ownership Of Bayshore
Strikes Deal To Acquire Remaining 20% Holding In US Generics Firm
Ipca has struck a deal to take full ownership of US firm Bayshore Pharmaceuticals by acquiring the remaining 20% stake that it did not already own.
You may also be interested in...
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.
India’s Ipca is boosting its API business with a deal to acquire local firm Ramdev Chemical for INR1.1bn in cash.
Ipca Laboratories has paid just under US$10.3 million in cash for 80% of the share capital in US generics player Bayshore Pharmaceuticals. The Indian company said that acquiring the majority stake in sales and marketing firm Bayshore through its wholly-owned US subsidiary Ipca Pharmaceuticals would “enable the firm to commercialise its registered generic drug products in the US market through this entity”.